A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
=== Anti-gp210 and anti-p62 === Both anti-glycoprotein-210 (anti-gp210) and anti-nucleoporin 62 (anti-p62) antibodies are antibodies to components of the nuclear membrane and are found in primary biliary cirrhosis (PBC). Each antibody is present in approximately 25–30% of PBC. The antigens of both antibodies are constituents of the nuclear membrane. gp210 is a 200kDa protein involved in anchoring components of the nuclear pore to the nuclear membrane. The p62 antigen is a 60kDa nuclear pore complex.
=== Blood supply === The liver gets its blood supply from the hepatic portal vein and hepatic arteries. The hepatic portal vein delivers around 75% of the liver's blood supply and carries venous blood drained from the spleen, gastrointestinal tract, and its associated organs. The hepatic arteries supply arterial blood to the liver, accounting for the remaining quarter of its blood flow. Oxygen is provided from both sources; about half of the liver's oxygen demand is met by the hepatic portal vein, and half is met by the hepatic arteries. The hepatic artery also has both alpha- and beta-adrenergic receptors; therefore, flow through the artery is controlled, in part, by the splanchnic nerves of the autonomic nervous system. Blood flows through the liver sinusoids and empties into the central vein of each lobule. The central veins coalesce into hepatic veins, which leave the liver and drain into the inferior vena cava.
==== Hillary Clinton's 2008 and 2016 presidential campaigns ==== After running for Congress in 1998, Pritzker transitioned away from electoral politics, becoming a significant donor to Democratic candidates. In this role he first met former First Lady and then-U.S. Senator Hillary Clinton, hosting a fundraiser at his Chicago home for her 2006 reelection campaign. When Clinton ran for president in 2008, she named Pritzker a national co-chair of her campaign. After Clinton withdrew from the race, he supported the party's nominee, Barack Obama, helping merge the Clinton and Obama campaigns in Illinois. While Pritzker had no official role in Clinton's 2016 presidential campaign, he was one of her largest donors, giving more than $17.5 million to her super PAC and campaign combined. Pritzker and his wife were also in attendance at Clinton's watch party in the Javits Center when she conceded the 2016 election to Donald Trump.
== Prevention == No prevention mechanism exists for Sjögren's disease (SjD) because of its complexity as an autoimmune disorder. However, lifestyle changes can reduce the risk factors related to developing SjD or reduce the severity of the condition for patients who have already been diagnosed. Diet is strongly associated with the inflammation seen in many autoimmune-related diseases, including SjD. An experimental study concluded that SjD patients often show high gluten sensitivity that directly relates to inflammation. Moderate exercise is also helpful in SjD patients, mainly reducing the effect of lung inflammation.
Sources: en.wikipedia.org
Berry steps down from the post in order to run as Green candidate in Brighton Pavilion, where current MP Caroline Lucas is standing down at the next election. 8 May – John Swinney is sworn in as Scotland's seventh first minister at a ceremony at the Court of Session in Edinburgh. Swinney appoints Kate Forbes as Scotland's Deputy First Minister. The Conservative Member of Parliament for Dover Natalie Elphicke defects to the Labour Party. The Labour whip is restored to Kate Osamor. Former England cricketer Monty Panesar quits the Workers Party of Britain a week after being unveiled as one of its general election candidates. MSs vote 43–16 to approve the Senedd Reform Bill that will see the number of members increase from 60 to 96 at the next election. 9 May – Former cabinet minister Nadhim Zahawi says he will stand down from Parliament at the next election. Natalie Elphicke apologises for past comments in support of her ex-husband, Charlie, which she made when he was convicted of sexual assault. Swinney confirms to the BBC that the SNP's strategy of using the next general election as a mandate for a second referendum on Scottish independence remains. The government announces that a ban on sex offenders in England and Wales changing their name to avoid detection will be brought in. 10 May – The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted.
== Early life == Lila Moss was born in London, United Kingdom. She is the daughter of model Kate Moss and magazine editor Jefferson Hack, who co-founded Dazed. Her parents split up shortly after her birth. She attended the Parsons School of Design in New York.
Weapons-grade nuclear material is any fissionable nuclear material that is pure enough to make a nuclear weapon and has properties that make it particularly suitable for nuclear weapons use. Plutonium and uranium in grades normally used in nuclear weapons are the most common examples. (These nuclear materials have other categorizations based on their purity.) Only fissile isotopes of certain elements have the potential for use in nuclear weapons. For such use, the concentration of fissile isotopes uranium-235 and plutonium-239 in the element used must be sufficiently high. Uranium from natural sources is enriched by isotope separation, and plutonium is produced in a suitable nuclear reactor. Experiments have been conducted with uranium-233 (the fissile material at the heart of the thorium fuel cycle). Neptunium-237 and some isotopes of americium might be usable, but it is not clear that this has ever been implemented. The latter substances are part of the minor actinides in spent nuclear fuel.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.